Lantheus Medical Imaging, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$18.2M
Doctors Paid
7,253
Transactions
23,115
2024 Total
$1.9M
Payment Breakdown by Category
Research$4.7M (26.0%)
Consulting$1.2M (6.6%)
Travel$883,207 (4.9%)
Food & Beverage$555,103 (3.1%)
Royalty/License$25,000 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10.3M | 2,038 | 56.5% |
| Unspecified | $4.7M | 648 | 26.0% |
| Consulting Fee | $1.2M | 150 | 6.6% |
| Travel and Lodging | $883,207 | 3,371 | 4.9% |
| Food and Beverage | $555,103 | 16,360 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $226,245 | 136 | 1.2% |
| Grant | $130,710 | 30 | 0.7% |
| Gift | $110,734 | 96 | 0.6% |
| Debt forgiveness | $35,012 | 43 | 0.2% |
| Royalty or License | $25,000 | 1 | 0.1% |
| Education | $15,485 | 241 | 0.1% |
| Charitable Contribution | $1,030 | 1 | 0.0% |
Payments by Type
General
$13.4M
22,467 transactions
Research
$4.7M
634 transactions
Ownership
$0
14 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| DEF-314 Better Accuracy in EF Assessment With DEFINITY BENEFIT1 | $1.0M | 0 | 84 |
| DEF-315 Better Accuracy in EF Assessment With DEFINITY BENEFIT2 | $930,072 | 0 | 122 |
| DEF-315 Better Accuracy in EF Assessment With DEFINITY (BENEFIT2) | $400,117 | 0 | 55 |
| EXPANDED ACCESS TREATMENT WITH (LU-177)-PNT2002 FOR ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) | $230,322 | 0 | 17 |
| DEF-314 Better Accuracy in EF Assessment With DEFINITY (BENEFIT1) | $192,315 | 0 | 26 |
| Amendment #4 to Research Agree | $118,491 | 0 | 3 |
| 2D and 4D Contrast-Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization | $109,219 | 0 | 23 |
| UTILIZATION OF ULTRASOUND ENHANCING AGENTS IN A NATIONWIDE COHORT | $96,613 | 0 | 4 |
| Ultrasound Cavitation for Treating Non-healing Ischemic Ulcers in Patients with Critical Limb Ischemia | $84,398 | 0 | 5 |
| Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging | $81,495 | 0 | 11 |
| ULTRASOUND CAVITATION FOR TREATING NON-HEALING ISCHEMIC ULCERS IN PATIENTS WITH CRITICAL LIMB ISCHEMIA | $81,253 | 0 | 5 |
| Quantitative Subharmonic Breast Imaging: 3D Subharmonic Pressure Estimation for Prediction of Neoadjuvant Chemotherapy Response | $58,553 | 0 | 14 |
| QUANTITATIVE SUBHARMONIC BREAST IMAGING 3D SUBHARMONIC PRESSURE ESTIMATION FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE | $52,915 | 0 | 9 |
| Microvascular Recovery with Ultrasound in Acute Myocardial Infarction Trial Post PCI Trial | $52,646 | 0 | 2 |
| NONINVASIVE SUBHARMONIC AIDED PRESSURE ESTIMATION OF PORTAL HYPERTENSION | $46,788 | 0 | 6 |
| QUANTITATIVE SUBHARMONIC BREAST IMAGING: 3D SUBHARMONIC PRESSURE ESTIMATION FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE | $45,723 | 0 | 8 |
| Utility of Contrast in Routine Clinical Echocardiography of Heart Failure | $45,000 | 0 | 2 |
| Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy | $43,194 | 0 | 16 |
| Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients with CKD CEUS CKD | $40,683 | 0 | 6 |
| Cross-Sectional Study of Contrast-Enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients with Von Hippel-Lindau | $36,904 | 0 | 8 |
| Role of physical activity in restoring vascular insulin sensitivity in skeletal muscle of patients with type 2 diabetes | $34,719 | 0 | 6 |
| A FEASIBILITY STUDY EXAMINING THE USE OF NON-INVASIVE FOCUSED ULTRASOUND (FUS) WITH ORAL ETOPOSIDE ADMINISTRATION IN CHILDREN WITH PROGRESSIVE DIFFUSE MIDLINE GLIOMA (DMG) | $34,001 | 0 | 4 |
| RTMPE in the ICU The Impact of Real-Time Myocardial Perfusion Echocardiography on Diagnostic Confidence and Subsequent Management of Myocardial Ischemia in the Intensive Care Unit | $33,296 | 0 | 7 |
| Pilot Study of Noninvasive Cardiac Pressure Measurements Using Subharmonic Microbubbles Signals | $26,474 | 0 | 6 |
| PROSTATE CANCER DIAGNOSIS BY MULTIPARAMETRIC ULTRASOUND (WHOLEMOUNT) | $25,465 | 0 | 4 |
| Protocol # 021FSGS16010 | $24,537 | 3 | 36 |
| Sex-related differences in arterial stiffness in type 2 diabetics: role of uric acid | $22,883 | 0 | 10 |
| Microbubble Mediated Ultrasonic Therapy for Microvascular Obstruction | $21,858 | 0 | 1 |
| AN OPEN-LABEL, PHASE 3, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FLUBROBENGUANE F18 PET IMAGING IN PATIENTS WITH KNOWN OR SUSPECTED NEUROBLASTOMA | $21,500 | 0 | 2 |
| Microvascular Effects of Long Duration Space Missions | $21,168 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. James Thrall, Md, MD | Nuclear Medicine | Boston, MA | $1.3M | $0 |
| Derace Schaffer, M.d, M.D | Diagnostic Radiology | Rochester, NY | $1.0M | $0 |
| Dr. Eyal Herzog, M.d, M.D | Cardiovascular Disease | New York, NY | $822,715 | $0 |
| Dr. Frederick Robertson, M.d, M.D | Pediatric Anesthesiology | Madison, WI | $486,159 | $0 |
| Robert Biederman, Md, MD | Cardiovascular Disease | Charleston, SC | $378,150 | $0 |
| Steven Mottl, D.o, D.O | Internal Medicine | Tucson, AZ | $310,223 | $0 |
| Dr. Paul Bhella, M.d, M.D | Cardiovascular Disease | Grapevine, TX | $284,847 | $0 |
| Dr. Rajesh Janardhanan, Md, Mrcp, Facc, Fase, MD, MRCP, FACC, FASE | Internal Medicine | Tucson, AZ | $273,258 | $0 |
| Jayanta Mukherjee, Md, MD | Internal Medicine | Columbus, OH | $192,148 | $0 |
| Dr. Martin Goldman, M.d, M.D | Specialist | New York, NY | $189,376 | $0 |
| Robert Fowles, M.d, M.D | Cardiovascular Disease | Salt Lake City, UT | $188,011 | $0 |
| Kamran Shaikh, M.d, M.D | Cardiovascular Disease | Kyle, TX | $185,455 | $0 |
| Dr. Joan Crawford, Do, DO | Internal Medicine | Bloomington, IN | $179,346 | $0 |
| Issam Mikati, Md, MD | Cardiovascular Disease | Chicago, IL | $169,574 | $0 |
| Frederman Concepcion, M.d, M.D | Cardiovascular Disease | Chicago, IL | $127,002 | $0 |
| Dionisios Mihalatos, M.d, M.D | Cardiovascular Disease | Roslyn, NY | $95,592 | $0 |
| Unknown Provider | — | — | $95,548 | $0 |
| Dr. Rafel Rieves, Md, MD | Health Service | Washington, DC | $92,524 | $0 |
| Dr. James Ford, M.d, M.D | Interventional Cardiology | Paducah, KY | $86,448 | $0 |
| Andrew Zurick, M.d, M.D | Hospitalist | Nashville, TN | $81,677 | $0 |
| Dr. Gabriel Vorobiof, Md, MD | Cardiovascular Disease | Los Angeles, CA | $80,951 | $0 |
| Dr. Amr Abbas, M.d, M.D | Interventional Cardiology | Berkley, MI | $62,364 | $0 |
| Dr. Robert Capodilupo, M.d, M.D | Cardiovascular Disease | Manchester, NH | $58,792 | $0 |
| Mani Vannan, Mbbs, MBBS | Cardiovascular Disease | Atlanta, GA | $58,296 | $0 |
| Jayant Nath, Md, MD | Cardiovascular Disease | Kansas City, KS | $51,686 | $0 |
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. has made $18.2M in payments to 7,253 healthcare providers, recorded across 23,115 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is Definity ($5.6M).
Payments were distributed across 115 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($3.2M to 2,554 doctors).
Payment categories include: Food & Beverage ($555,103), Consulting ($1.2M), Research ($4.7M), Travel & Lodging ($883,207), Royalties ($25,000).
Lantheus Medical Imaging, Inc. is associated with 4 products in the CMS Open Payments database, including Definity, DEFINITY, and QUADRAMET.